Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron plus aprepitant versus palonosetron for prevention of chemotherapy-induced nausea and vomiting in AML or high-risk MDS
2011-003823-36Phase 2Active
- Sponsor
- Associazione Angela Serra (Salento)
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in chemotherapy-induced nausea and vomiting (CINV) comparing Palonosetron plus aprepitant with Palonosetron alone (2 arms). Started Mar 2012; status: active.
02
Drugs
palonosetronaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2011-003823-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003823-36.